

Appendix 6 Full results – costs*, effects and cost-effectiveness of interventions

		WHO African sub-region AfrE				WHO south-east Asian sub-region SearD			
		Annual DALYs saved per 1 million population	Annual cost (I\$) per capita	Average CER (I\$ per DALY averted, relative to no intervention)	Incremental CER (I\$ per DALY averted, within intervention cluster)	Annual DALYs saved per 1 million population	Annual cost (I\$) per capita	Average CER (I\$ per DALY averted, relative to no intervention)	Incremental CER (I\$ per DALY averted, within intervention cluster)
CVD prevention: control of tobacco use									
TOB-1	Current Scenario (tax at current rates)	412	0.31	747	Dominated	2,284	0.27	116	Dominated
TOB-2	Increased taxation	687	0.31	448	448	3,043	0.27	87	87
TOB-3	Comprehensive advertising ban	119	0.17	1,394	Dominated	701	0.13	187	Dominated
TOB-4	Clean indoor air laws	101	0.14	1,365	Dominated	667	0.11	162	Dominated
TOB-5	Information and labelling	200	0.31	1,570	Dominated	1,164	0.23	195	Dominated
TOB-6	Nicotine Replacement therapy	30	0.38	12,770	Dominated	184	0.62	3,362	Dominated
TOB-7	Brief advice	31	0.12	3,875	Dominated	188	0.18	958	Dominated
TOB-8	Counselling	35	0.16	4,663	Dominated	201	0.24	1,179	Dominated
TOB-9	Tax increase + Ad Ban	786	0.45	573	Dominated	3,650	0.38	103	Dominated
TOB-10	Tax increase + Clean indoor air	768	0.42	552	Dominated	3,617	0.36	98	156
TOB-11	Tax increase + Information/labelling	864	0.59	683	Dominated	4,102	0.47	114	Dominated
TOB-12	Tax increase + NRT	699	0.66	938	Dominated	3,147	0.84	268	Dominated
TOB-13	Tax increase + Brief advice	699	0.41	581	Dominated	3,150	0.42	134	Dominated
TOB-14	Tax increase + Counselling	703	0.45	634	Dominated	3,163	0.48	151	Dominated
TOB-15	Tax increase + Ad Ban + Clean Indoor Air	885	0.58	658	1,384	4,300	0.48	112	182
TOB-16	Tax increase + Ad Ban + Info/labelling	980	0.75	763	Dominated	4,785	0.59	124	Dominated
TOB-17	Tax increase + Ad Ban + NRT	815	0.81	998	Dominated	3,830	0.97	252	Dominated
TOB-18	Tax increase + Ad Ban + Brief advice	816	0.56	691	Dominated	3,833	0.55	143	Dominated
TOB-19	Tax increase + Ad Ban + Counselling	819	0.60	737	Dominated	3,846	0.60	157	Dominated
TOB-20	Tax increase + Clean indoor air + Info/labelling	963	0.72	750	Dominated	4,752	0.57	120	Dominated
TOB-21	Tax increase + Clean indoor air + NRT	797	0.79	987	Dominated	3,796	0.94	249	Dominated
TOB-22	Tax increase + Clean indoor air + Brief advice	798	0.54	673	Dominated	3,800	0.53	138	Dominated
TOB-23	Tax increase + Clean indoor air + Counselling	802	0.58	720	Dominated	3,812	0.58	152	Dominated
TOB-24	Tax increase + Info/labelling + NRT	893	0.95	1,067	Dominated	4,282	1.06	247	Dominated
TOB-25	Tax increase + Info/labelling + Brief advice	894	0.70	787	Dominated	4,285	0.64	149	Dominated
TOB-26	Tax increase + Info/labelling + Counselling	898	0.74	828	Dominated	4,298	0.69	161	Dominated
TOB-27	Tax increase + Ad Ban + Clean Indoor Air + Info/labelling	1,051	0.86	815	1,645	5,296	0.68	128	198
TOB-28	Tax increase + Ad Ban + Clean Indoor Air + NRT	890	0.92	1,034	Dominated	4,365	1.04	238	Dominated

TOB-29	Tax increase + Ad Ban + Clean Indoor Air + Brief advice	891	0.68	760	Dominated	4,368	0.63	145	Dominated
TOB-30	Tax increase + Ad Ban + Clean Indoor Air + Counselling	895	0.72	800	Dominated	4,381	0.69	157	Dominated
TOB-31	Tax increase + Clean Indoor Air + Info/labelling + NRT	967	1.06	1,093	Dominated	4,805	1.13	235	Dominated
TOB-32	Tax increase + Clean Indoor Air + Info/labelling + Brief advice	967	0.81	841	Dominated	4,808	0.72	150	Dominated
TOB-33	Tax increase + Clean Indoor Air + Info/labelling + Counselling	971	0.85	877	Dominated	4,821	0.77	161	Dominated
TOB-34	Tax increase + Ad Ban + Clean Indoor Air + Info/labelling + NRT	1,051	1.18	1,120	Dominated	5,327	1.22	228	Dominated
TOB-35	Tax increase + Ad Ban + Clean Indoor Air + Info/labelling + Brief advice	1,052	0.94	894	Dominated	5,330	0.82	154	4,176
TOB-36	Tax increase + Ad Ban + Clean Indoor Air + Info/labelling + Counselling	1,056	0.98	927	28,082	5,342	0.87	163	4,229
CVD prevention and treatment									
CVD-1	Reduced dietary salt intake - voluntary (15%)	276	0.16	591	Dominated	330	0.07	197	Dominated
CVD-2	Reduced dietary salt intake - legislated (30%)	509	0.16	321	Dominated	0	0.07	901,991	Dominated
CVD-3	Reduced population-level cholesterol via mass media campaign	472	0.27	581	Dominated	805	0.15	191	Dominated
CVD-4	Individual drug treatment for hypertension (SBP > 140) + education	4,616	1.81	393	Dominated	4,128	2.00	484	Dominated
CVD-5	Individual drug treatment for hypertension (SBP > 160) + education	3,317	0.47	141	Dominated	2,409	0.34	142	Dominated
CVD-6	Individual cholesterol treatment (> 5.7 mmol/l)	1,862	1.37	734	Dominated	3,692	3.18	862	Dominated
CVD-7	Individual cholesterol treatment (> 6.2 mmol/l)	1,346	0.78	582	Dominated	2,729	1.87	683	Dominated
CVD-8	Preventive multi-drug treatment (>5% risk of CVD event)	5,817	2.33	401	3,931	7,271	3.84	528	1,817
CVD-9	Combination drug treatment (>15% risk of CVD event)	4,504	0.96	212	Dominated	5,340	1.68	314	Dominated
CVD-10	Combination drug treatment (>25% risk of CVD event)	3,689	0.51	139	Dominated	3,979	0.80	201	Dominated
CVD-11	Preventive multi-drug treatment (>35% risk of CVD event)	3,163	0.33	104	104	2,984	0.41	138	146
CVD-12	Combination of population-based hypertension & cholesterol control (CVD-1 + CVD-3)	989	0.37	370	Dominated	1,416	0.19	135	Dominated
CVD-13	Combination of individual-based hypertension & cholesterol control (CVD-5 + CVD-7)	4,132	0.90	218	Dominated	4,764	2.21	464	Dominated

CVD treatment: Acute care of IHD / stroke									
CVD-14	Treatment of acute MI in hospital with aspirin	59	0.11	1,809	Dominated	243	0.17	697	Dominated
CVD-16	Treatment of acute MI in hospital with ACE inhibitors	17	0.13	7,303	Dominated	71	0.20	2,790	Dominated
CVD-18	Treatment of acute MI in hospital with β -Blockers	10	0.13	12,742	Dominated	40	0.20	4,856	Dominated
CVD-21	Treatment of acute MI in hospital with thrombolysis (streptokinase)	64	0.15	2,379	Dominated	263	0.27	1,033	Dominated
CVD-22	Treatment of acute MI in hospital with primary PTCA (angioplasty)	149	0.27	1,821	Dominated	615	0.56	908	Dominated
CVD-40	Treatment of acute MI with aspirin + PTCA	173	0.27	1,580	Dominated	711	0.56	788	Dominated
CVD-41	Treatment of acute MI with aspirin + streptokinase	108	0.15	1,413	Dominated	443	0.27	614	Dominated
CVD-47	Treatment of acute MI with aspirin + ACEI + streptokinase	117	0.15	1,311	Dominated	483	0.28	572	Dominated
CVD-49	Treatment of acute MI with aspirin, ACEI + PTCA	178	0.27	1,537	Dominated	732	0.56	768	Dominated
CVD-50	Treatment of acute MI with aspirin, B-blocker + ACEI	79	0.13	1,610	Dominated	325	0.20	620	Dominated
CVD-33	Treatment of acute MI with aspirin + β -Blocker + ACEi + Streptokinase	122	0.15	1,257	Dominated	504	0.28	549	Dominated
CVD-39	Treatment of acute MI with ASA + β -Blocker + ACEI + PTCA	180	0.27	1,515	Dominated	743	0.56	757	Dominated
CVD-49	Treatment of acute MI with aspirin, ACEI + PTCA	178	0.27	1,537	Dominated	732	0.56	768	Dominated
CVD-50	Treatment of acute MI with aspirin, B-blocker + ACEI	79	0.13	1,610	Dominated	325	0.20	620	Dominated
CVD-28	Organised stroke unit care	43	0.80	18,555	Dominated	54	0.85	15,772	Dominated
CVD-24	Treatment of acute ischemic stroke in hospital with aspirin	17	0.64	38,133	Dominated	22	0.67	30,182	Dominated
CVD treatment: Secondary prevention of IHD / stroke									
CVD-15	Treatment of post-acute IHD with aspirin	16	0.06	4,085	Dominated	77	0.06	714	Dominated
CVD-17	Treatment of post-acute IHD with ACE inhibitors	55	0.08	1,464	Dominated	250	0.14	565	Dominated
CVD-19	Treatment of post-acute IHD with β -Blockers	51	0.07	1,316	Dominated	237	0.08	319	Dominated
CVD-20	Treatment of post-acute IHD with statins	27	0.07	2,433	Dominated	135	0.07	539	Dominated
CVD-43	Treatment of post-acute IHD with aspirin + β -Blocker	67	0.07	1,025	Dominated	312	0.08	265	Dominated
CVD-42	Treatment of post-acute IHD with aspirin + β -Blocker + Statin	93	0.07	791	Dominated	428	0.10	244	Dominated
CVD-34	Treatment of post-acute IHD with aspirin + β -Blocker + statin + ACEI	151	0.10	637	Dominated	666	0.22	329	Dominated

CVD-51	Treatment of post-acute IHD with aspirin, B-Blocker + ACEI	125	0.08	616	Dominated	553	0.12	217	Dominated
CVD-52	Treatment of post-acute IHD with aspirin, B-Blocker + Cardiac rehab	138	0.08	556	Dominated	607	0.10	167	Dominated
CVD-53	Treatment of post-acute IHD with aspirin, B-Blocker, ACEI + Statin	151	0.08	547	Dominated	666	0.14	217	Dominated
CVD-23	Cardiac rehabilitation for post-acute IHD	66	0.06	917	Dominated	307	0.04	123	Dominated
CVD-25	Treatment of post-acute stroke with aspirin	159	0.09	571	Dominated	221	0.07	330	Dominated
CVD-26	Treatment of post-acute stroke with statins	308	0.11	353	Dominated	392	0.10	258	Dominated
CVD-46	Treatment of post-acute stroke with aspirin + statin	461	0.11	248	Dominated	582	0.11	185	Dominated
CVD-27	Treatment of post-acute stroke with ACE-Inhibitor + diuretic	316	0.16	502	Dominated	419	0.18	436	Dominated
CVD-35	Treatment of post-acute stroke with aspirin + statin + ACEI + diuretic	745	0.19	249	Dominated	906	0.22	240	Dominated
CVD-37	Treatment of post-acute IHD and stroke with statins	335	0.12	354	Dominated	526	0.15	285	Dominated
CVD-48	Treatment of ischemic stroke and MI with aspirin	175	0.10	556	Dominated	298	0.10	347	Dominated
CVD-29	Treatment of CHF with diuretics	96	0.06	626	Dominated	402	0.03	81	81
CVD-30	Treatment of CHF with ACE inhibitors	11	0.06	6,110	Dominated	48	0.05	962	Dominated
CVD-31	Treatment of CHF with β -Blockers	22	0.08	3,603	Dominated	100	0.09	933	Dominated
CVD-32	Exercise training for persons with CHF	37	0.06	1,597	Dominated	165	0.03	208	Dominated
CVD-44	Treatment of CHF with diuretics + Exercise training	113	0.07	580	Dominated	462	0.05	109	Dominated
CVD-45	Treatment of CHF with diuretics + Exercise training + ACEI	116	0.07	627	Dominated	474	0.07	150	Dominated
CVD-36	Treatment of CHF with diuretics + exercise training + β -Blocker + ACEI	123	0.10	821	Dominated	497	0.15	301	Dominated
CVD-38	Treatment of post-acute IHD and stroke with aspirin + β -Blocker + Statin	553	0.13	229	Dominated	1,011	0.18	183	Dominated
CVD treatment & prevention packages									
CVD-54	Treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD (ASA, BB, Statin)	252	0.17	677	Dominated	1,047	0.36	343	Dominated
CVD-55	Treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD (ASA, BB, ACEI, Statin)	334	0.19	555	Dominated	1,347	0.40	296	Dominated
CVD-56	Treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD & stroke (ASA, BB, Statin)	706	0.22	317	Dominated	1,610	0.44	273	Dominated
CVD-57	Treatment of post-acute IHD & stroke (ASA, BB, Statin) + CHF (diuretics, exercise)	702	0.14	193	Dominated	1,544	0.21	138	Dominated
CVD-58	Treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD & stroke (ASA, BB, Statin) + CHF (diuretics, exercise)	912	0.23	256	Dominated	2,281	0.47	205	Dominated

CVD-59	Population-based prevention (CVD-12) + treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD (ASA, BB, Statin)	1,219	0.54	440	Dominated	2,376	0.55	231	Dominated
CVD-60	Population-based prevention (CVD-12) + treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD (ASA, BB, ACEI, Statin)	1,295	0.54	420	Dominated	2,661	0.59	222	Dominated
CVD-61	Population-based prevention (CVD-12) + treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD & stroke (ASA, BB, Statin)	1,644	0.59	359	Dominated	2,907	0.63	217	Dominated
CVD-62	Population-based prevention (CVD-12) + treatment of post-acute IHD & stroke (ASA, BB, Statin) + CHF (diuretics, exercise)	1,650	0.50	304	Dominated	2,898	0.40	139	Dominated
CVD-63	Population-based prevention (CVD-12) + treatment of acute MI (ASA, BB, ACEI, Strep) + Post-acute IHD & stroke (ASA, BB, Statin) + CHF (diuretics, exercise)	1,835	0.60	326	Dominated	3,544	0.66	186	Dominated
CVD-64	Individual-based prevention (CVD-13) + treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD (ASA, BB, Statin)	4,307	1.07	249	Dominated	5,526	2.57	465	Dominated
CVD-65	Individual-based prevention (CVD-13) + treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD (ASA, BB, ACEI, Statin)	4,368	1.08	247	Dominated	5,776	2.61	452	Dominated
CVD-66	Individual-based prevention (CVD-13) + treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD & stroke (ASA, BB, Statin)	4,626	1.13	244	Dominated	5,977	2.65	443	Dominated
CVD-67	Individual-based prevention (CVD-13) + treatment of post-acute IHD & stroke (ASA, BB, Statin) + CHF (diuretics, exercise)	4,656	1.04	223	Dominated	6,096	2.42	397	Dominated
CVD-68	Individual-based prevention (CVD-13) + treatment of acute MI (ASA, BB, ACEI, Strep) + Post-acute IHD & stroke (ASA, BB, Statin) + CHF (diuretics, exercise)	4,779	1.14	238	Dominated	6,533	2.68	410	Dominated
CVD-69	Combination drug treatment (>25% risk of CVD event) + treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD (ASA, BB, Statin)	4,474	0.75	167	Dominated	4,825	1.16	240	Dominated
CVD-70	Combination drug treatment (>25% risk of CVD event) + treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD (ASA, BB, ACEI, Statin)	4,719	0.76	160	Dominated	5,089	1.20	235	Dominated
CVD-71	Combination drug treatment (>25% risk of CVD event) + treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD & stroke (ASA, BB, Statin)	4,884	0.80	164	Dominated	5,267	1.24	235	Dominated
CVD-72	Combination drug treatment (>25% risk of CVD event) + treatment of post-acute IHD &	4,947	0.71	144	Dominated	5,299	1.01	191	Dominated

	stroke (ASA, BB, Statin) + CHF (diuretics, exercise)								
CVD-73	Preventive multi-drug therapy (>25% risk) + multi-drug treatment of acute MI / post-acute IHD & stroke + CHF (diuretics, exercise)	5,431	0.81	149	1,165	5,857	1.27	216	462
CVD-74	Combination drug treatment (>35% risk of CVD event) + treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD (ASA, BB, Statin)	4,118	0.55	135	Dominated	3,886	0.77	198	Dominated
CVD-75	Combination drug treatment (>35% risk of CVD event) + treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD (ASA, BB, ACEI, Statin)	4,408	0.56	128	Dominated	4,160	0.81	195	Dominated
CVD-76	Combination drug treatment (>35% risk of CVD event) + treatment of acute MI (ASA, BB, ACEI, Strep) + post-acute IHD & stroke (ASA, BB, Statin)	4,616	0.61	132	Dominated	4,355	0.85	195	Dominated
CVD-77	Preventive multi-drug therapy (>35% risk) + multi-drug treatment of post-acute IHD & stroke + CHF (diuretics, exercise)	4,649	0.52	112	129	4,386	0.62	142	152
CVD-78	Preventive multi-drug therapy (>35% risk) + multi-drug treatment of acute MI / post-acute IHD & stroke + CHF (diuretics, exercise)	5,265	0.62	117	158	5,016	0.88	175	404
Treatment of diabetes and its complications									
DM-2	Standard glycemc control (Standard GC)	1,075	1.02	944	Dominated	1,717	0.82	477	Dominated
DM-3	Intensive glycemc control (Intensive GC)	1,320	2.14	1,624	Dominated	2,044	1.77	867	Dominated
DM-4	Retinopathy screening + photocoagulation (Retinopathy)	1,228	1.00	814	814	1,891	0.32	170	170
DM-5	Neuropathy screening + preventive foot care (Neuropathy)	327	0.67	2,055	Dominated	721	0.42	585	Dominated
DM-6	Standard GC + Retinopathy	1,467	2.02	1,375	4,266	2,233	1.14	512	2,399
DM-7	Standard GC + Neuropathy	1,079	1.69	1,563	Dominated	1,721	1.24	721	Dominated
DM-8	Intensive GC + Retinopathy	1,529	3.17	2,070	18,419	2,319	2.11	912	11,348
DM-9	Intensive GC + Neuropathy	1,191	2.83	2,380	Dominated	1,865	2.21	1,186	Dominated
DM-10	Standard GC + Retinopathy + Neuropathy	1,353	2.69	1,987	Dominated	2,078	1.56	753	Dominated
DM-11	Intensive GC + Retinopathy + Neuropathy	1,389	3.93	2,827	Dominated	2,122	2.62	1,234	Dominated

- To convert international dollars to local currency units, the international dollar figure should be multiplied by the purchasing power parity (PPP) exchange rate. A list of PPP exchange rates developed by WHO for all members states can be found here: <http://www.who.int/choice/costs/ppp/en/index.html>

Appendix 7 CVD treatment strategies: cost per treated case

		WHO African sub-region AfrE		WHO South East Asian SearD	
		Treated cases	Annual cost per treated case (I\$)	Treated cases	Annual cost per treated case (I\$)
CVD prevention: control of high blood pressure and cholesterol					
CVD-4	Individual drug treatment for hypertension (SBP > 140) + education	18,006,451	40	78,537,678	35
CVD-5	Individual drug treatment for hypertension (SBP > 160) + education	3,427,049	55	10,553,021	45
CVD-6	Individual cholesterol treatment (> 5.7 mmol/l)	12,954,156	42	134,573,306	33
CVD-7	Individual cholesterol treatment (> 6.2 mmol/l)	6,983,432	45	82,841,197	31
CVD-8	Preventive multi-drug treatment (>5% risk of CVD event)	17,782,033	53	93,323,598	57
CVD-9	Combination drug treatment (>15% risk of CVD event)	6,698,900	57	36,124,877	64
CVD-10	Combination drug treatment (>25% risk of CVD event)	3,183,358	65	17,076,770	65
CVD-11	Preventive multi-drug treatment (>35% risk of CVD event)	1,647,781	80	8,684,418	66
CVD treatment: Acute care of IHD / stroke					
CVD-14	Treatment of acute MI in hospital with aspirin	64,310	667	636,937	368
CVD-16	Treatment of acute MI in hospital with ACE inhibitors	64,310	785	636,937	430
CVD-18	Treatment of acute MI in hospital with β -Blockers	64,310	783	636,937	427
CVD-21	Treatment of acute MI in hospital with thrombolysis (streptokinase)	64,310	950	636,937	591
CVD-22	Treatment of acute MI in hospital with primary PTCA (angioplasty)	64,310	1,701	636,937	1,217
CVD-40	Treatment of acute MI with aspirin + PTCA	64,310	1,705	636,937	1,221

CVD-41	Treatment of acute MI with aspirin + streptokinase	64,310	950	636,937	592
CVD-47	Treatment of acute MI with aspirin + ACEI + streptokinase	64,310	961	636,937	602
CVD-49	Treatment of acute MI with aspirin, ACEI + PTCA	64,310	1,708	636,937	1,225
CVD-50	Treatment of acute MI with aspirin, B-blocker + ACEI	64,310	795	636,937	439
CVD-33	Treatment of acute MI with aspirin + β -Blocker + ACEi + Streptokinase	64,310	962	636,937	603
CVD-39	Treatment of acute MI with ASA + β -Blocker + ACEI + PTCA	64,310	1,709	636,937	1,226
CVD-49	Treatment of acute MI with aspirin, ACEI + PTCA	64,310	1,708	636,937	1,225
CVD-50	Treatment of acute MI with aspirin, B-blocker + ACEI	64,310	795	636,937	439
CVD-28	Organised stroke unit care	167,911	1,904	764,470	1,539
CVD-24	Treatment of acute ischemic stroke in hospital with aspirin CVD treatment: Secondary prevention of IHD / stroke	167,911	1,529	764,470	1,222
CVD-15	Treatment of post-acute IHD with aspirin	293,545	87	293,545	260
CVD-17	Treatment of post-acute IHD with ACE inhibitors	293,545	109	4,397,400	45
CVD-19	Treatment of post-acute IHD with β -Blockers	293,545	92	4,397,400	24
CVD-20	Treatment of post-acute IHD with statins	293,545	91	4,397,400	23
CVD-43	Treatment of post-acute IHD with aspirin + β -Blocker	293,545	94	4,397,400	26
CVD-42	Treatment of post-acute IHD with aspirin + β -Blocker + Statin	293,545	100	4,397,400	33
CVD-34	Treatment of post-acute IHD with aspirin + β -Blocker + statin + ACEI	293,545	132	4,397,400	69
CVD-51	Treatment of post-acute IHD with aspirin, B-Blocker + ACEI	293,545	105	4,397,400	38

CVD-52	Treatment of post-acute IHD with aspirin, B-Blocker + Cardiac rehab	293,545	105	4,397,400	32
CVD-53	Treatment of post-acute IHD with aspirin, B-Blocker, ACEi + Statin	293,545	113	4,397,400	46
CVD-23	Cardiac rehabilitation for post-acute IHD	293,545	83	4,397,400	12
CVD-25	Treatment of post-acute stroke with aspirin	543,965	67	2,495,549	40
CVD-26	Treatment of post-acute stroke with statins	543,965	80	2,495,549	56
CVD-46	Treatment of post-acute stroke with aspirin + statin	543,965	84	2,495,549	60
CVD-27	Treatment of post-acute stroke with ACE-Inhibitor + diuretic	543,965	117	2,495,549	102
CVD-35	Treatment of post-acute stroke with aspirin + statin + ACEi + diuretic	543,965	137	2,495,549	121
CVD-37	Treatment of post-acute IHD and stroke with statins	258,786	185	3,853,846	54
CVD-48	Treatment of ischemic stroke and MI with aspirin	258,786	151	3,853,846	37
CVD-38	Treatment of post-acute IHD and stroke with aspirin + β -Blocker + Statin	258,786	197	3,853,846	67
CVD-29	Treatment of CHF with diuretics	100,368	241	860,317	52
CVD-30	Treatment of CHF with ACE inhibitors	100,368	258	860,317	75
CVD-31	Treatment of CHF with β -Blockers	100,368	318	860,317	150
CVD-32	Exercise training for persons with CHF	100,368	237	860,317	55
CVD-44	Treatment of CHF with diuretics + Exercise training	100,368	262	860,317	81
CVD-45	Treatment of CHF with diuretics + Exercise training + ACEi	100,368	292	860,317	115
CVD-36	Treatment of CHF with diuretics + exercise training + β -Blocker + ACEi	100,368	404	860,317	241